TENKASI

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug TENKASI contains one active pharmaceutical ingredient (API):

1 Oritavancin UNII PUG62FRZ2E - ORITAVANCIN

Oritavancin is used for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Read about Oritavancin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TENKASI Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J01XA05		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XA Glycopeptide antibacterials
Discover more medicines within J01XA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1680960, 3044113
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 433794
Country: FR	Base de données publique des médicaments	Identifier(s): 67623773, 68529070
Country: IT	Agenzia del Farmaco	Identifier(s): 044015016, 044015028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1076035
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100342536